Kawahara, T.; Hasizume, A.; Uemura, K.; Yamaguchi, K.; Ito, H.; Takeshima, T.; Hasumi, H.; Teranishi, J.-i.; Ousaka, K.; Makiyama, K.;
et al. Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma. Cancers 2023, 15, 4227.
https://doi.org/10.3390/cancers15174227
AMA Style
Kawahara T, Hasizume A, Uemura K, Yamaguchi K, Ito H, Takeshima T, Hasumi H, Teranishi J-i, Ousaka K, Makiyama K,
et al. Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma. Cancers. 2023; 15(17):4227.
https://doi.org/10.3390/cancers15174227
Chicago/Turabian Style
Kawahara, Takashi, Akihito Hasizume, Koichi Uemura, Katsuya Yamaguchi, Hiroki Ito, Teppei Takeshima, Hisashi Hasumi, Jun-ichi Teranishi, Kimito Ousaka, Kazuhide Makiyama,
and et al. 2023. "Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma" Cancers 15, no. 17: 4227.
https://doi.org/10.3390/cancers15174227
APA Style
Kawahara, T., Hasizume, A., Uemura, K., Yamaguchi, K., Ito, H., Takeshima, T., Hasumi, H., Teranishi, J.-i., Ousaka, K., Makiyama, K., & Uemura, H.
(2023). Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma. Cancers, 15(17), 4227.
https://doi.org/10.3390/cancers15174227